DOCK3 and cancer: Although it is not desirable to fully activate RAC1 in every tissue due to its role as a known cancer-driving oncogenic factor [37], temporal and tissue-specific modulation of active RAC1 may be beneficial for rescuing some of the DOCK3-affected pathways that are altered in patients.